维普中文期刊产品整合服务

Special Section:SARS-CoV-2 Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

查看全文 作　　者：Mingxing [1]Huang;Man [2,3]Li;Fei [1,2]Xiao;Pengfei [2,3]Pang;Jiabi [4]Liang;Tiantian [5]Tang;Shaoxuan [6]Liu;Binghui [7]Chen;Jingxian [4]Shu;Yingying [8]You;Yang [2,3]Li;Meiwen [9]Tang;Jianhui [10]Zhou;Guanmin [10]Jiang;Jingfen [11]Xiang;Wenxin [12]Hong;Songmei [13]He;Zhaoqin [14]Wang;Jianhua [15]Feng;Changqing [16]Lin;Yinong [17]Ye;Zhilong [18]Wu;Yaocai [19]Li;Bei [20]Zhong;Ruilin [21]Sun;Zhongsi [1]Hong;Jing [22]Liu;Huili [1]Chen;Xiaohua [23]Wang;Zhonghe [24]Li;Duanqing [25,26]Pei;Lin [3]Tian;Jinyu [1]Xia;Shanping [5]Jiang;Nanshan [27]Zhong;Hong [2,3]Shan 高影响力作者 机构地区：[1]Departnent of Infectious Dseases,The Fifth Affiliated Hospital,Sun Yat-sen University,Zhuhai 519000,China;[2]Guangdong Provinctal Key Laboratory of Bomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular lmaging,The Fifth Afflated Hospital,Sun Yat-sen Universrty,Zhuhai 519000,China;[3]Center for Interventional Medictne,The Fifth Affiliated Hospital,Sun Yat-sen Unuversrty,Zhuhai 519000,China;[4]Department of Pharmacy,The Fifth Affiluated Hosprtal,Sun Yat-sen University,Zhuhai 519000,China;[5]Department of Respuratory and Critical Care Medicine,Sun Yat-sen Menorral Hosprtal,Sun Yat-sen Unrversity,Guangzhou 510120,China;[6]Clncal Research Center Office,The Fifth Affillated Hospstal,Sun Yat-sen Unlversity,Zhuhai 519000,China;[7]Department of Radiology,The Fifth Affiltated Hospital,Sun Yat-sen Universrty,Zhuhai 519000,China;[8]Department of Stomatology,The Fifth Affilated Hospital,Sun Yat-sen Unverslty,Zhuhai 519000,China;[9]Department of Hemiatology,The Fifth Affilated Hospital,Sun Yat-sen University,Zhuhai 519000,China;[10]Department of Clnscal laboratory,The Ffith Affiliated Hospital,Sun Yat-sen Unrversty,Zhuhai 519000,China;[11]Department of Emergency,Wuhan East West Lake Mobule Cabin Hosprtals,Wuhan 430040,China;[12]Department of Infectous Diseases,Guangzhou Eighth People's Hospital,Guangzhou 510060,China;[13]Department of lnfectious Diseases,Dongguan Nnth People's Hospital,Dongguan 532016,China;[14]Departinent of Infectious Diseases,Shenzlhen Third People's Hospital,Shenzhen 518100,China;[15]Department of Infectious Diseases,Zhongshan Second People's Hospital,Zhongshan 528447;[16]China;[17]Department of espraory artcal Care Medicne,Huzhou Cential People's Hosprtal,Huuzhou 516001,China;[18]Department of Infectious Diseases,Foshan First People's Hospital,Foshan 528000,China;[19]Department of espratoy ac Cttical Care Medicue,The Fourth People's Hospital of Foshan City,Foshan 528000,China;[20]Department of Infectious Diseases,Maomng People's Hospital,Maoming 525000,China;[21]Departnent of Infectious Dnseases,Maomng People's Hospital,Maoming 525000,China;[22]Department of Infectious Diseases,The SixthAffilated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,ngyuan 511518,China;[23]Puimonary and Critical Care Medicine Departnent,Guangdong Second ProvInctal General Hospital,Guangzhou 510317,China;[24]Department of Respiratory and Cutical Care Medicine,The Fifth Affilated Hosprtal,Sun Yat-sen University,Zhuhai 519099,China;[25]Intensive Care Unit,The Fifth Affiliated Hospital,Sun Yat-sen University,Zhuhai 519099,China;[26]Guangzhou Institutes of Btomedicine and Health,Chtnese Academy of Sclences,Guangzhou 51070O,China;[27]State Key Laboratory of Respiratory DIseases,Guangzhou Insttute of Respiratory Health,The Furst Affrliated Hospital of Guangzhou Medcal Unversity,Guangzhou 510120,China高影响力机构 出　　处：《National Science Review》索引2020年第7卷第9期,共9页高影响力期刊 基　　金：This work was supported in part by the National Key Research and Development Plan for the Emergency Management of Novel Coronavirus Pneumonia(2020YFC082400);the Special Project of Guangdong Science and Technology Department(2020B111105001);the Emergency Research Project on SARS-CoV-2 from Guangzhou Regenerative Medicine and Health Guangdong Laboratory(2020GZR110106003);the Cultivation project of Scientific Research Plan from'Three Major Constructions of Sun Yat-sen University in 2020':Emergency Management of Novel Coronavirus Pneumonia in Science and Technology Development;the Emergency Project of Novel Coronavirus Pneumonia in Science and Technology Development of Zhuhai in 2020. 摘　　要：Effective therapies are urgently needed for the SARS-CoV-2 pandemic.Chloroquine has been proved to have antiviral effect against coronavirus in vitro.In this study,we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19.In this multicenter prospective observational study,we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces.Eligible patients received chloroquinephosphate s00 mg,orally,once(half dose)or twice(full dose)daily.Patients treated with non-chloroquine therapy were included as historical controls.The primary endpoint is the time to undetectable viral RNA.Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14,hospitalization time,duration of fever,and adverse events.A total of 197 patients completed chloroquine treatment,and 176patients were included as historical controls.The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine(absolute difference in medians-6.0 days;95%CI-6.0 to—4.0).The duration of fever is shorter in chloroquine(geometric mean ratio 0.6;95%CIO.5 to 0.8).No serious adverse events were observed in the chloroquine group.Patients treated with half dose experienced lower rate of adverse events than with full dose.Although randomized trials are needed for further evaluation,this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic. 关 键 词：COVID-19 SARS-CoV-2 TREATMENT CHLOROQUINE
相关文献

参考文献(25)

引证文献(22)

耦合文献(618)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费